Results from the positive phase III AVAglio study
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the positive phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo (HR=0.64; p<0.0001) in people with newly diagnosed glioblastoma,
Bayer's "Perspective on Innovation 2012"
- Details
- Category: Bayer
With numerous new products, the Bayer Group aims to help improve people's lives while exploiting billions in potential sales. "Innovation is the only way to address the global challenges that exist at the beginning of the third millennium," Management Board Chairman Dr. Marijn Dekkers said on Wednesday, addressing some 140 journalists at Bayer's "Perspective on Innovation 2012" forum in Leverkusen.
Sanofi and T1D Exchange to launch worldwide study
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and T1D Exchange, a non-profit organization focused on type 1 diabetes, will collaborate on the TEENs registry study. The aim of the study is to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes, and to deliver recommendations for better disease management and patients outcomes.
Bristol-Myers Squibb Foundation's Together on Diabetes™ marks World Diabetes Day
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation has marked World Diabetes Day and the second anniversary of its Together on Diabetes™ initiative by issuing the initiative's second annual report and awarding two new grants to partners in India.
The largest clinical study of Bayer's Xarelto® (rivaroxaban)
- Details
- Category: Bayer
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto® (rivaroxaban) to date, investigating the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).
Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner's proprietary pipeline
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim's biopharmaceutical contract manufacturing business and Molecular Partners have entered into a strategic manufacturing collaboration. Under the terms of the agreement, Boehringer Ingelheim will be responsible for the generation of E. coli production strains and the manufacture of tox and clinical stage material for multiple DARPin® products supplying Molecular Partners proprietary DARPin® pipeline.
Novartis future growth prospects secured by industry-leading pipeline
- Details
- Category: Novartis
Novartis has provided an update on its leading Research and Development (R&D) pipeline and plans for turning these assets into commercial success to provide the basis for continued growth of the Group through 2017. Continuing R&D productivity in the Pharmaceuticals Division has fueled an industry-leading pipeline with 139 projects in clinical development with more than 73 New Molecular Entities (NMEs) across a multitude of disease areas.
More Pharma News ...
- Results from the largest known cholesterol survey conducted in the U.S.
- Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola's universal Factor Xa inhibitor antidote PRT4445
- Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D
- Novartis to start construction of new biotechnology facility in Singapore
- Bayer on track for a successful 2012
- GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma
- The Respimat® success story: Boehringer Ingelheim doubles its production capacity